Would you change chemotherapy to VIP in a young patient with stage IIIB intermediate risk non-seminomatous germ cell tumor with borderline DLCO after one cycle of BEP?   

The term “borderline DLCO” needs to be taken into context. The test is not completely reliable and one needs to consider the DLCO result in the clinical setting - has the patient been a heavy smoker, does he have known respiratory disease, does he have any limitation in effort tolerance,...

I generally agree with Dr. @Derek Raghavan. There is an Australian study showing that those with lower received doses of bleomycin had worse therapeutic outcomes.In truth, I do not do PFTs each cycle of therapy but do follow them closely with physical exam (lung auscultation for findings of fine ral...